Clinical Trial Update: Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015 [Phase 3]

View source ↗

Summary

A 52-week extension phase (Phase 3) assessed the safety of the buprenorphine transdermal system in subjects with chronic low back pain; the trial was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low Back Pain

Drugs mentioned

• BUPRENORPHINE TRANSDERMAL SYSTEM (buprenorphine)

Snippet

Sponsor: Purdue Pharma LP | Conditions: Back Pain Lower Back Chronic | Phase 3 | Status: TERMINATED | Results posted: 2010-09-21